Join
Live feed
·
INSIDERFilingvia Quantisnow
Fate Therapeutics Inc. logo

Director Redmile Group, Llc converted options into 30,110 shares (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
FATE· Fate Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FATE (Fate Therapeutics Inc.) and more on Quantisnow.

Director Redmile Group, Llc converted options into 30,110 shares (SEC Form 4) | Quantisnow